141 related articles for article (PubMed ID: 20594126)
1. Role of IL-21 in inflammatory bowel disease.
Pallone F; Fina D; Caruso R; Monteleone G
Expert Rev Clin Immunol; 2010 Jul; 6(4):537-41. PubMed ID: 20594126
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-21 as a new therapeutic target for immune-mediated diseases.
Monteleone G; Pallone F; Macdonald TT
Trends Pharmacol Sci; 2009 Aug; 30(8):441-7. PubMed ID: 19616319
[TBL] [Abstract][Full Text] [Related]
3. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells.
Caruso R; Fina D; Peluso I; Stolfi C; Fantini MC; Gioia V; Caprioli F; Del Vecchio Blanco G; Paoluzi OA; Macdonald TT; Pallone F; Monteleone G
Gastroenterology; 2007 Jan; 132(1):166-75. PubMed ID: 17241869
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-21 in T cell-mediated diseases.
Monteleone G; Sarra M; Pallone F
Discov Med; 2009 Oct; 8(42):113-7. PubMed ID: 19833056
[TBL] [Abstract][Full Text] [Related]
5. IL-22 and inflammation: leukin' through a glass onion.
Zenewicz LA; Flavell RA
Eur J Immunol; 2008 Dec; 38(12):3265-8. PubMed ID: 19016525
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease.
Ouyang W
Cytokine Growth Factor Rev; 2010 Dec; 21(6):435-41. PubMed ID: 21106435
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts.
Andoh A; Zhang Z; Inatomi O; Fujino S; Deguchi Y; Araki Y; Tsujikawa T; Kitoh K; Kim-Mitsuyama S; Takayanagi A; Shimizu N; Fujiyama Y
Gastroenterology; 2005 Sep; 129(3):969-84. PubMed ID: 16143135
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-21 in chronic inflammatory diseases.
Sarra M; Pallone F; Monteleone G
Biofactors; 2013; 39(4):368-73. PubMed ID: 23553807
[TBL] [Abstract][Full Text] [Related]
9. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells.
Hoeve MA; Savage ND; de Boer T; Langenberg DM; de Waal Malefyt R; Ottenhoff TH; Verreck FA
Eur J Immunol; 2006 Mar; 36(3):661-70. PubMed ID: 16482511
[TBL] [Abstract][Full Text] [Related]
10. A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice.
Jang E; Cho SH; Park H; Paik DJ; Kim JM; Youn J
J Immunol; 2009 Apr; 182(8):4649-56. PubMed ID: 19342640
[TBL] [Abstract][Full Text] [Related]
11. The role of the novel Th17 cytokine IL-26 in intestinal inflammation.
Dambacher J; Beigel F; Zitzmann K; De Toni EN; Göke B; Diepolder HM; Auernhammer CJ; Brand S
Gut; 2009 Sep; 58(9):1207-17. PubMed ID: 18483078
[TBL] [Abstract][Full Text] [Related]
12. New mediators of immunity and inflammation in inflammatory bowel disease.
Monteleone G; Fina D; Caruso R; Pallone F
Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
[TBL] [Abstract][Full Text] [Related]
13. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
Gordon JN; Di Sabatino A; Macdonald TT
Curr Opin Gastroenterol; 2005 Jul; 21(4):431-7. PubMed ID: 15930983
[TBL] [Abstract][Full Text] [Related]
14. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
15. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses.
Habib T; Nelson A; Kaushansky K
J Allergy Clin Immunol; 2003 Dec; 112(6):1033-45. PubMed ID: 14657853
[TBL] [Abstract][Full Text] [Related]
16. Biology of IL-21 and the IL-21 receptor.
Mehta DS; Wurster AL; Grusby MJ
Immunol Rev; 2004 Dec; 202():84-95. PubMed ID: 15546387
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
18. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
van Deventer SJ
Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1956-9. PubMed ID: 9550744
[TBL] [Abstract][Full Text] [Related]
19. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease.
Atreya R; Atreya I; Neurath MF
Ann N Y Acad Sci; 2006 Aug; 1072():98-113. PubMed ID: 17057193
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease.
Monteleone G; Pallone F; Macdonald TT
Cytokine Growth Factor Rev; 2009 Apr; 20(2):185-91. PubMed ID: 19261537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
